Stoke Therapeutics

26 articles with Stoke Therapeutics

• Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources

  10/16/2019

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced the appointments of Robin A. Walker, J.D., as Senior Vice President and Chief Legal Officer, and Joan Wood as Head of Human Resources.

• Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference

  9/30/2019

  Stoke Therapeutics, Inc. announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 10:05 a.m. Eastern time in New York, New York.

• Stoke Therapeutics Added to Russell 2000 and 3000 Indexes

  9/11/2019

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that it has been added to the Russell 2000® and 3000® indexes effective September 20, 2019

• Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome

  8/20/2019

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced enrollment of the first patient in an observational study of children and adolescents ages 2 to 18 with Dravet syndrome.

• Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

  8/14/2019

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the second quarter of 2019.

• Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome

  8/6/2019

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product candidate, STK-001, an investigational new treatment for Dravet syndrome.

• Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference

  8/1/2019

  Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at 9:00 a.m. ET in Boston, Mass.

• Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  6/21/2019

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its initial public offering of 9,074,776 shares of its common stock at a price to the public of $18.00

• 

  Six Biotech Companies with IPOs This Week

  6/21/2019

  This week marked initial public offering news from six biopharma companies. Here’s a look.

• Stoke Therapeutics Announces Pricing of Initial Public Offering

  6/18/2019

  Stoke Therapeutics, Inc. announced the pricing of its initial public offering of 7,891,110 shares of its common stock at a price to the public of $18.00 per share.

• Stoke Therapeutics Appoints Jennifer Burstein to its Board of Directors

  6/14/2019

  Stoke Therapeutics, Inc., a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Jennifer Burstein to its board of directors.

• 

  Stoke Therapeutics Files for $86 Million IPO

  5/24/2019

  Stoke focuses on treating genetic diseases by upregulating protein expression. Its lead compound, STK-001, is focused on Dravet syndrome, a rare form of epilepsy that starts in infancy.

• Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer

  3/19/2019

  Stoke Therapeutics, Inc. announced the appointment of Stephen J. Tulipano, CPA, MBA as chief financial officer.

• Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

  2/26/2019

  --Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure--   [26-February-2019]   SAN FRANCISCO , Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions,

• Stoke Therapeutics to Present on First Precision Treatments for Genetic Epilepsies at J.P. Morgan Healthcare Conference

  1/3/2019

  Stoke Therapeutics will present on its pioneering work to develop the first gene-specific, disease-modifying therapies for genetic epilepsies at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco next week.

• Stoke Therapeutics Expands Senior Leadership Team, Adding Deep Expertise in Regulatory Affairs and Clinical Operations

  12/18/2018

  Company also relocating to expanded R&D facilities at 45 Wiggins Ave. in Bedford, Mass.

• Stoke Therapeutics Presents Data Showing Single Dose of ASO Therapy Restores Normal Protein Levels in Animal Model of Genetic Epilepsy

  12/1/2018

  Stoke Therapeutics and research collaborators from the University of Michigan today present data demonstrating the efficacy of Stoke’s proprietary antisense oligonucleotide (ASO) technology in treating Dravet Syndrome in mouse models.

• Stoke Therapeutics to Present New Data on Lead Program at American Epilepsy Society's 2018 Annual Meeting

  11/27/2018

  Stoke Therapeuticss and research collaborators from the University of Michigan will present new preclinical data supporting Stoke’s development of its antisense oligonucleotide technology to treat Dravet Syndrome at the annual meeting of the American Epilepsy Society in New Orleans.

• Stoke Therapeutics Announces $90 Million Series B Financing to Advance Novel Oligonucleotide Medicines

  10/23/2018

  Lead candidate to treat the genetic cause of Dravet Syndrome expected to reach clinic by 2020

• Stoke Therapeutics to Present Research Supporting Advancement of Dravet Syndrome Program at Annual Meeting of the Oligonucleotide Therapeutics Society

  9/27/2018

  Stoke Therapeutics, Inc. will present research at the upcoming annual meeting of the Oligonucleotide Therapeutics Society supporting its approach of leveraging antisense oligonucleotides to increase protein expression for the treatment of Dravet Syndrome and other monogenic diseases.